What Chugai Pharma UK does

Chugai Pharma UK, operating under the legal name Chugai Pharma Europe Ltd., is a regional pharmaceutical subsidiary headquartered in Turnham Green, London. Founded in 1993, it is a wholly-owned subsidiary of Tokyo-listed Chugai Pharmaceutical Co., Ltd. and operates within the strategic Chugai–Roche alliance. The company focuses on three core therapy areas — haemophilia, oncology, and rheumatology — providing innovative pharmaceutical products aimed at addressing unmet medical needs in the UK and broader European market.

Its commercial offering centres on branded specialty medicines distributed through institutional channels, principally the NHS under a dedicated partnership programme. The company also maintains pharmacovigilance, medical affairs, and UK regulatory functions to support MHRA-compliant distribution and post-market safety oversight. Research and development activity is referenced on the UK site, but core drug discovery and pipeline ownership sit with the Tokyo parent; no specific product SKUs, proprietary technology platforms, or platform architecture details are disclosed in available source material.

The business model is a conventional specialty-pharma regional distribution and medical-affairs model: revenue is generated through NHS and institutional procurement of prescription medicines, with pricing negotiated rather than publicly disclosed. There are no disclosed B2C channels, no consumer-facing apps, no recurring SaaS-style pricing, and no indication of independent fundraising — capital and strategic direction flow from the Tokyo parent. Operational scale is small, at approximately 30 employees, consistent with a lean regional affiliate rather than a standalone commercial-stage pharma company.

Name

Chugai Pharma UK

Legal name

Chugai Pharma Europe Ltd.

Website

https://chugai-pharm.co.uk

Company type

Private

Founded year

1993

Operating status

Operating

Headcount range

11–50 employees

Short description

Chugai Pharma UK (Chugai Pharma Europe Ltd.) is a London-headquartered regional pharmaceutical subsidiary of Tokyo-listed Chugai Pharmaceutical Co., Ltd., distributing specialty medicines in haemophilia, oncology, and rheumatology primarily to the NHS under the Chugai–Roche alliance.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industry

Specialty Pharma & Biologics Distribution (GDP-compliant) (HLAGAMAD)

Keywords

• Pharmaceutical products
• Oncology treatments
• Haemophilia therapies
• Rheumatology medicines
• Prescription drugs

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure

Distribution channels1 record

Marketing channels3 records

Core offering

Chugai Pharma UK operates as the regional European arm of Chugai Pharmaceutical Co., Ltd., developing and supplying prescription pharmaceutical products for the UK market. Its core therapeutic focus is on haemophilia, oncology, and rheumatology, delivering innovative medicines for unmet medical needs. The company also conducts research and development activities and provides pharmacovigilance services in support of its marketed products.

Product overview

Chugai Pharma UK, operating as Chugai Pharma Europe, is a pharmaceutical company that develops and delivers medicines in core therapy areas of haemophilia, oncology, and rheumatology. The company offers UK medicines, conducts research and development, and provides pharmacovigilance services. The portfolio consists of pharmaceutical products for unmet medical needs, though no specific named drug products are detailed on the available source pages.

Differentiator

Problem solved

Functional benefit

Products and services

• UK Medicines Portfolio Portfolio of prescription pharmaceutical products developed and supplied to the UK market in the core therapy areas of haemophilia, oncology, and rheumatology, addressing unmet medical needs.
• Pharmacovigilance Services

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Two partnerships are on record, tiered core.

• RochecoreStrategic or Co-development PartnerStrategic alliance between Chugai Pharmaceutical Co., Ltd. (Tokyo) and Roche. Chugai Pharma Europe operates as a wholly owned subsidiary of the Tokyo-based parent company, benefiting from the global Roche alliance for research, development, and commercial operations.
• NHS (National Health Service)coreStrategic or Co-development PartnerDedicated partnership programme for working with the NHS on healthcare solutions. The company has extensive experience in partnership working on healthcare solutions with NHS institutions, offering flexibility and capabilities in medicine supply and collaboration.

Scale indicators1 record

Recent moves4 records

Expansion highlights4 records

Direct peers

• Sobi (Swedish Orphan Biovitrum): Swedish specialty biopharma with deep haemophilia and rare-disease franchises; directly comparable to Chugai Pharma UK as a focused specialty player commercializing high-unmet-need therapies in Europe.

Others

• Roche UK: UK subsidiary of Roche, the strategic alliance partner of Chugai's parent company; comparable as a UK specialty/oncology pharma arm and as the parent-partner's own UK commercialization infrastructure.

Broad incumbents

• Novartis UK: UK arm of Novartis with strong oncology and rheumatology portfolios; comparable as a global innovator pharma distributing branded specialty medicines in the UK through NHS and private channels.
• Sanofi UK: UK arm of Sanofi with established haemophilia, rare-disease, and oncology specialty assets; comparable in therapeutic overlap and as a global pharma distributing innovative specialty medicines through NHS pathways.
• GSK: UK-headquartered global pharmaceutical company with specialty oncology and immunology portfolios; comparable as a large UK-based pharma commercializing branded specialty therapies.
• Bayer UK: UK subsidiary of Bayer with established haemophilia franchise and broader specialty pharma presence; comparable in therapeutic overlap (haemophilia) and as a multinational pharma UK distribution arm.
• Takeda UK: UK arm of Takeda, a global pharma with rare-disease, oncology, and specialty portfolios; overlaps with Chugai Pharma UK's therapeutic focus areas while operating at a much larger scale.
• AbbVie UK: UK subsidiary of AbbVie with a leading rheumatology/immunology franchise; comparable in therapeutic overlap (rheumatology) and as a multinational pharma operating branded specialty biologics in the UK.
• Pfizer UK: UK arm of Pfizer with major oncology and rheumatology/immunology franchises; comparable as a large multinational commercializing innovative specialty therapeutics in the same therapy areas as Chugai Pharma UK.

Regional players

• Astellas Pharma Ltd. (UK): UK arm of Japanese-headquartered Astellas with a strong oncology specialty franchise; comparable as another Japan-rooted pharma distributing specialty therapeutics in UK/Europe.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

• Xx.com/ChugaiEurope
• LinkedInlinkedin.com/company/chugai-pharm

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Chugai Pharma UK